Giant Biogene Holding Co (HKSE:02367) Accounts Payable & Accrued Expense : HK$538 Mil (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Giant Biogene Holding Co Accounts Payable & Accrued Expense?

Giant Biogene Holding Co's quarterly accounts payable & accrued expense increased from Dec. 2022 (HK$277 Mil) to Jun. 2023 (HK$351 Mil) and increased from Jun. 2023 (HK$351 Mil) to Dec. 2023 (HK$538 Mil).

Giant Biogene Holding Co's annual accounts payable & accrued expense declined from Dec. 2021 (HK$8,350 Mil) to Dec. 2022 (HK$277 Mil) but then increased from Dec. 2022 (HK$277 Mil) to Dec. 2023 (HK$538 Mil).

Giant Biogene Holding Co Accounts Payable & Accrued Expense Historical Data

The historical data trend for Giant Biogene Holding Co's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Giant Biogene Holding Co Accounts Payable & Accrued Expense Chart

Giant Biogene Holding Co Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

690.34

2,572.43

8,350.29

276.77

537.92

Giant Biogene Holding Co Semi-Annual Data
	Dec19	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial			8,350.29	-	276.77	350.96	537.92

Giant Biogene Holding Co Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Giant Biogene Holding Co (HKSE:02367) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Giant Biogene Holding Co Ltd (HKSE:02367) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 1855, Shanglin Yuan 7th Road, Chang’an District, Shaanxi Province, Xi’an, CHN

Website

http://www.xajuzi.com

Giant Biogene Holding Co Ltd design, develop and manufacture professional skin treatment products with recombinant collagen as the key bioactive ingredient. The company also develops and manufactures rare ginsenosides technology-based functional foods. The company utilizes proprietary synthetic biology technology to develop and manufacture multiple types of recombinant collagen and rare ginsenosides in-house. Bioactive ingredients offer a wealth of beauty and health properties such as skin repair, anti-aging, whitening, moisturizing and immunity improvement with a broad range of applications in the beauty and health sectors.

Executives

Refulgence Holding Limited	2201 Interest of corporation controlled by you
Juzi Holding Co., Ltd	2101 Beneficial owner
Fan Daidi	2201 Interest of corporation controlled by you
Yan Jianya	2202 Interest of your spouse
Yi Fang Da Ji Jin Guan Li You Xian Gong Si	2102 Investment manager
Yan Jianya	2101 Beneficial owner
Fan Daidi
Trident Trust Company (b.v.i.) Limited	2301 Trustee

Giant Biogene Holding Co (HKSE:02367) Headlines

No Headlines